Eskridge, Wayne; Cryer, Donna R.; Schattenberg, Joern M. et al.
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician PerspectiveJOURNAL OF CLINICAL MEDICINE. Bd. 12. H. 19. 2023
Gairing, Simon Johannes; Mangini, Chiara; Zarantonello, Lisa et al.
Minimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survivalJOURNAL OF INTERNAL MEDICINE. 2023
Gairing, Simon Johannes; Mangini, Chiara; Zarantonello, Lisa et al.
Minimal Hepatic Encephalopathy Is Associated With an Increased Risk of Overt Hepatic Encephalopathy and Poorer Prognosis - A Multicenter StudyAMERICAN JOURNAL OF GASTROENTEROLOGY. Bd. 118. H. 9S. 2023 S. S9-S9
Penzkofer, Lea; Groeger, Lisa-Katharina; Hoppe-Lotichius, Maria et al.
Mixed Hepatocellular Cholangiocarcinoma: A Comparison of Survival between Mixed Tumors, Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma from a Single CenterCANCERS. Bd. 15. H. 3. 2023
Haber, Philipp K.; Castet, Florian; Torres-Martin, Miguel et al.
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular CarcinomaGASTROENTEROLOGY. Bd. 164. H. 1. 2023
Tomalla, Vanessa; Schmeisser, Michael J.; Weinmann-Menke, Julia
Mouse models, antibodies, and neuroimaging: Current knowledge and future perspectives in neuropsychiatric systemic lupus erythematosus (NPSLE)FRONTIERS IN PSYCHIATRY. Bd. 14. 2023
Schattenberg, Joern M.; Balp, Maria-Magdalena; Reinhart, Brenda et al.
NASHmap: clinical utility of a machine learning model to identify patients at risk of NASH in real-world settingsSCIENTIFIC REPORTS. Bd. 13. H. 1. 2023
Wu, Linda; Fulgenzi, Claudia A. M.; D'Alessio, Antonio et al.
Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. 2023 S. 504-504
Janjigian, Yelena Y.; Shitara, Kohei; Moehler, Markus H. et al.
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 16. 2023
Janjigian, Yelena Y.; Shitara, Kohei; Moehler, Markus H. et al.
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. 2023 S. 291-291